Wed07172019

Robins Global News & Noticias



  • Gaming Chair Review
    Gaming Chair Review
  • Data Recovery Review
    Data Recovery Review
  • Online Video Editors
    Online Video Editors
  • Download TV Series
    Download TV Series
  • All Elite Wrestling
    All Elite Wrestling
  • Trump Pence News
    Trump Pence News
  • Weather Alerts
    Weather Alerts

RobinsPost News Network

+ Larger Font | + Smaller Font

Globe NewsWire News Distribution Service

Press Release: INmune Bio Reports First Quarter 2019 Financial Results and Provides Shareholder Update


LA JOLLA, Calif., May 15, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today reported its financial results and is providing a business update for the first quarter ended March 31, 2019.
Corporate Highlights in 2019:First biotechnology company to close initial public offering in 2019 and commence trading on The Nasdaq Capital Market.Received the Part the Cloud Award from the Alzheimer’s Association, including a $1 million grant to advance XPro1595, a novel therapy targeting neuroinflammation as a cause of Alzheimer’s disease.“2019 has marked a transformative period for INmune Bio, as the first biotech of the year to close its IPO and list on the Nasdaq,” stated RJ Tesi, M.D., Chief Executive Officer of INmune Bio. “We are focused on advancing our clinical programs for the foreseeable future.” Our clinical programs continue to advance:INB03, our program targeting resistance to immunotherapy caused by myeloid derived suppressor ells (MDSC), completing a monotherapy Phase I trial in patients with advanced solid tumors, will transition into a combination therapy clinical program this summer in preparation for a Phase II trial in patients resistant to checkpoint inhibitors due to increased MDSC that should begin in 2020.  INB03 targets MDSC - one of the causes of resistance to checkpoint inhibitors.  Treatment with INB03 should eliminate the MDSC in the tumor microenvironment to allow CPI to be therapeutically effective.INKmune, our NK cell therapy focused on eliminating residual disease after cancer therapy will start enrolling patients in a Phase I/II trial in women with relapsed refractory ovarian cancer later this year.  In many patients, cancer relapse after seemingly effective cancer therapy is due to a failure of their NK cells to eliminate minimal residual disease (MRD).  INKmune, by priming the patient’s NK cells to attack their tumor, should eliminate MRD to prevent relapse.


Posted: 2019-05-15 13:03:00

Get Full News Story On GlobeNewsWire Press Release Service


Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.


Print Friendly and PDF Share Embed


Related News Stories From The Web And More

Related Bing News

Press Release: INmune Bio Reports First Quarter 2019 Financial Results and Provides Shareholder Update | Globe NewsWire News Distribution Service | RobinsPost News Network - Newscast

Exxe Group Inc. Announces Shareholder Letter and Company Vision

Wed, 17 Jul 2019 07:35:00 GMT

NEW YORK, July 17, 2019 (GLOBE NEWSWIRE ... sustainable technology, media, financial services and agriculture, today released a shareholder letter providing a snapshot of the Company’s ...

Melinta Therapeutics Announces Preliminary Second Quarter 2019 Financial Results and Provides Corporate Update

Tue, 16 Jul 2019 15:25:00 GMT

today reported preliminary and unaudited financial results and provided a corporate update for the second quarter ended June 30, 2019. “Melinta’s preliminary second quarter 2019 results ...

Mercantile Bank Corporation (MBWM) CEO Bob Kaminski on Q2 2019 Results - Earnings Call Transcript

Tue, 16 Jul 2019 10:36:00 GMT

Mercantile Bank Corporation (NASDAQ:MBWM) Q2 2019 Results Earnings ... On the call, we will provide an update on our overall performance and financial results along with our key areas of strategic ...

Ford Motor Company: Details of Ford Motor Company Briefing on 2019 Second Quarter Results

Mon, 15 Jul 2019 17:31:00 GMT

July 15, 2019 ... Ford chief financial officer; and members of Ford's senior management team will host a conference call at 5:30 p.m. ET to discuss the results. The presentation and supporting ...

People Corporation Announces Financial Results for the Third Quarter of Fiscal 2019

Mon, 15 Jul 2019 04:30:00 GMT

WINNIPEG, Manitoba, July 15, 2019 (GLOBE ... growth and shareholder returns, while leveraging its increasing scale to provide clients with a leading suite of solutions and unparalleled experience." ...

Related Twitter Search

  • No items found
  • Related News Story Videos From Youtube

    ‘Complete manipulation’ by Elon Musk’s Tesla short-sellers


    Related Videos On: ‘Complete manipulation’ by Elon Musk’s Tesla short-sellers


    Tesla Q1 2019 Earnings Call (no ads)


    Related Videos On: Tesla Q1 2019 Earnings Call (no ads)


    2019 Annual Meeting of Stockholders


    Related Videos On: 2019 Annual Meeting of Stockholders


    Walmart's 2019 Shareholder Meeting [FULL]


    Related Videos On: Walmart's 2019 Shareholder Meeting [FULL]


    2019 Annual Shareholders’ Meeting


    Related Videos On: 2019 Annual Shareholders’ Meeting






    Blow Us A Whistle

    Comments (Whistles) Designed By Disqus




    Company Information

    Official Content Providers











    PRIVACY POLICY

    We recommend Firefox 3 (and above), Edge, and Chrome for dynamic performance.
    © 2008-2019 RobinsPost (The Bird's Eye View Company) All rights are reserved.
    RobinsPost provides links to news sites based on their RSS feeds.
    All trademarks, copyrights, videos, photos and logos are owned by news sources.
    News stories, videos and live streams are from trusted sources:
    Bing News, Google News, Faroo News, NewsApi.org and YouTube Search Results.
    ROBINSPOST Is Proudly Made In America.
    Where Quality, Safety and Service Comes First.